PALO ALTO, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. announced today that Nathaniel M. Zilkha has been elected to the Company’s Board of Directors, effective October 4, 2007. The Company also announced that Adam H. Clammer has resigned from its Board of Directors effective October 3, 2007.
Mr. Zilkha is a Principal at Kohlberg Kravis Roberts & Co. L.P., where he is a member of the Health Care industry team. Prior to joining KKR earlier this year, Mr. Zilkha was a Vice President in the Principal Investment Area of Goldman Sachs, where he executed and monitored private equity investments on behalf of the GS Capital Partners family of funds and led the group’s efforts in Healthcare and Life Sciences. In his eight years in the Principal Investment Area, Mr. Zilkha was also involved with transactions across a range of other sectors, including energy, media, industrial and technology.
“We are very pleased to welcome Nat Zilkha to the Jazz Pharmaceuticals Board of Directors,” said Bruce C. Cozadd, Executive Chairman of Jazz Pharmaceuticals. “On behalf of Jazz Pharmaceuticals’ Board of Directors and management team, I thank Adam Clammer for his many contributions since joining our Board in February 2004.”
About Jazz Pharmaceuticals, Inc. Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry. For further information, please visit http://www.JazzPharmaceuticals.com.
CONTACT: Karen L. Bergman, +1-650-575-1509, or Michelle Corral,
+1-415-794-8662, both of BCC Partners for Jazz Pharmaceuticals, Inc.; or
Jim Karrels, Executive Director, Finance of Jazz Pharmaceuticals, Inc.,
+1-650-496-2800, investorinfo@jazzpharma.com
Web site: http://www.jazzpharmaceuticals.com/
